# Platform Trial of Novel Regimens Versus Standard of Care (SoC) in Participants With Non-small Cell Lung Cancer (NSCLC) - Sub-study 3

> **NCT06926673** · PHASE2 · COMPLETED · sponsor: **GlaxoSmithKline** · enrollment: 62 (actual)

## Conditions studied

- Neoplasms

## Interventions

- **DRUG:** Dostarlimab
- **DRUG:** Belrestotug.
- **DRUG:** Nelistotug

## Key facts

- **NCT ID:** NCT06926673
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-12-23
- **Primary completion:** 2024-05-02
- **Final completion:** 2024-05-02
- **Target enrollment:** 62 (ACTUAL)
- **Last updated:** 2025-07-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06926673

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06926673, "Platform Trial of Novel Regimens Versus Standard of Care (SoC) in Participants With Non-small Cell Lung Cancer (NSCLC) - Sub-study 3". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT06926673. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*